A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

NCT ID: NCT01705483

Last Updated: 2024-11-07

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-08-28
• Study Completion Date: 2014-06-11

Brief Summary

The purpose of this study is to determine the safety and tolerability and pharmacokinetics of ASP9853 combined with docetaxel or with paclitaxel in subjects with advanced non-hematologic malignancies.

Detailed Description

This is a two part study. Part 1 will test increasing dose levels of ASP9853 in combination with docetaxel. Part 2 will test increasing doses of ASP9853 combined with paclitaxel. Each part will determine the maximum tolerated dose and recommended Phase 2 dose for ASP9853 in combination with each taxane. Preliminary evidence of antitumor activity of ASP9853 in combination with docetaxel or with paclitaxel also will be explored.

Conditions

Pharmacokinetics of ASP9853; Non-hematologic Malignancies

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Part 1: ASP9853 with docetaxel

2 docetaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts

Group Type: EXPERIMENTAL

ASP9853

Intervention Type: DRUG

oral

Docetaxel

Intervention Type: DRUG

intravenous (IV)

Part 2: ASP9853 with paclitaxel

Starting dose for ASP9853 determined as one dose level below maximum tolerated dose (MTD) determined in Part 1, 2 paclitaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts

Group Type: EXPERIMENTAL

ASP9853

Intervention Type: DRUG

oral

Paclitaxel

Intervention Type: DRUG

Taxol

Interventions

ASP9853

oral

Intervention Type: DRUG

Docetaxel

intravenous (IV)

Intervention Type: DRUG

Paclitaxel

Taxol

Intervention Type: DRUG

Other Intervention Names

Taxotere; intravenous (IV)

Eligibility Criteria

Inclusion Criteria

• Subject must have a histologically or cytologically confirmed incurable, locally advanced, or metastatic non-hematologic malignancy that has progressed or failed to respond to regimens or therapies known to provide clinical benefit
• Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• Subject must have recovered from the effects of prior systemic antineoplastic or radiation therapy(s) to ≤ Grade 1 severity or to subject's baseline values, excluding alopecia
• Subject agrees not to participate in another interventional study while on treatment

Female subject must be either:

Of non child bearing potential:

• post-menopausal (defined as at least 1 year without any menses) prior to Screening or
• documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening)

Or, if of childbearing potential:

• must have a negative serum pregnancy test at Screening and
• must use two forms of birth control (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 28 days after final study drug administration

Acceptable forms include:

• Established use of oral, injected or implanted hormonal methods of contraception.
• Placement of an intrauterine device (IUD) or intrauterine system (IUS).
• Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps) with spermicidal
• foam/gel/film/cream/suppository
• Female subject must not donate ova starting at Screening and throughout the study period and for 28 days after final study drug administration.
• Male subject must not donate sperm starting at Screening and throughout the study period and for 28 days after final study drug administration.
• Subject with adequate bone marrow, renal, and hepatic function at baseline

Exclusion Criteria

• Subject has received more than 3 prior cytotoxic agent-containing regimens
• Subjects with prior anaphylactic or hypersensitivity reaction to prior taxane therapy
• Subject with symptomatic central nervous system (CNS) metastases or leptomeningeal involvement
• Subjects who received treatments with any of the following:

• Systemic chemotherapy within 21 days
• Nitrosoureas or mitomycin C within 42 days
• Radiotherapy to ≥ 25% of hematopoietically active bone marrow within 21 days
• Subject had major surgical procedure within 28 days or anticipates need for major surgical procedure during course of the study
• Female subjects who are breastfeeding at Screening or during the study period and for 28 days after final study drug administration.
• Subject with peripheral neuropathy > Grade 1 at baseline
• Subject with known hepatitis B surface antigen (HBsAg) positive status; or known or suspected active hepatitis C infection; or known human immunodeficiency virus (HIV) positive
• Subject with malabsorption syndrome or disease or condition significantly affecting gastrointestinal function
• Subject with significant or uncontrolled cardiac, renal, hepatic or other systemic disorders, or significant psychological conditions at baseline
• Subject with clinically significant electrocardiogram (ECG) abnormalities on 12 lead ECG performed within 14 days before start of study drug
• Subject who has received strong inhibitors or inducers of CYP3A4 within two weeks prior to start of study treatment and while on study
• Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half lives, whichever is longer, prior to the initiation of Screening

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Astellas Pharma Global Development, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Astellas Pharma Global Development

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer Center

Detroit, Michigan, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Countries

United States

Related Links

https://astellasclinicalstudyresults.com/study.aspx?ID=302

Link to results on the Astellas Clinical Study Results website

Other Identifiers

9853-CL-0101

Identifier Type: -

Identifier Source: org_study_id